Shenzhen - Delayed Quote CNY
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)
16.79
+0.32
+(1.94%)
At close: 3:04:18 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1.34B
1.34B
1.15B
1.15B
1.09B
Cost of Revenue
583.50M
600.36M
468.15M
486.28M
454.48M
Gross Profit
757.65M
735.79M
684.88M
660.31M
637.46M
Operating Expense
670.52M
645.64M
552.93M
576.85M
591.85M
Operating Income
87.13M
90.15M
131.95M
83.46M
45.61M
Net Non Operating Interest Income Expense
55.33M
43.58M
59.65M
67.25M
87.17M
Pretax Income
218.52M
215.95M
420.21M
118.36M
137.12M
Tax Provision
31.87M
29.99M
58.39M
24.76M
15.01M
Net Income Common Stockholders
180.65M
184.53M
361.83M
93.61M
122.11M
Basic EPS
0.70
0.72
1.40
0.36
0.48
Diluted EPS
0.70
0.72
1.40
0.36
0.48
Basic Average Shares
257.79M
256.29M
258.45M
256.96M
255.15M
Diluted Average Shares
257.79M
256.29M
258.45M
256.96M
255.15M
Total Operating Income as Reported
224.20M
221.65M
419.81M
118.06M
136.91M
Total Expenses
1.25B
1.25B
1.02B
1.06B
1.05B
Net Income from Continuing & Discontinued Operation
180.65M
184.53M
361.83M
93.61M
122.11M
Normalized Income
190.34M
195.10M
178.69M
138.24M
135.52M
Interest Income
58.45M
47.13M
60.53M
68.25M
87.60M
Interest Expense
2.09M
2.66M
745.83k
875.18k
320.50k
Net Interest Income
55.33M
43.58M
59.65M
67.25M
87.17M
EBIT
220.62M
218.60M
420.96M
119.24M
137.44M
EBITDA
220.62M
299.78M
488.27M
185.36M
197.64M
Reconciled Cost of Revenue
583.50M
600.36M
468.15M
486.28M
454.48M
Reconciled Depreciation
--
81.17M
67.31M
66.12M
60.20M
Net Income from Continuing Operation Net Minority Interest
180.65M
184.53M
361.83M
93.61M
122.11M
Total Unusual Items Excluding Goodwill
-11.34M
-12.27M
212.69M
-56.43M
-15.06M
Total Unusual Items
-11.34M
-12.27M
212.69M
-56.43M
-15.06M
Normalized EBITDA
231.96M
312.05M
275.57M
241.79M
212.71M
Tax Rate for Calcs
0.15
0.14
0.14
0.21
0.11
Tax Effect of Unusual Items
-1.65M
-1.70M
29.55M
-11.80M
-1.65M
12/31/2021 - 4/23/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade